Overview

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost